In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep's (ASX:IMM) Executive Director and CEO, Marc Voigt.

Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.

In this video Marc discusses:

• (0:40) What IMM does and its key strength in the market
• (1:27) The impact of the FDA's recent feedback on its lead product
• (2:53) IMM's collaborations with big pharma names like Pfizer & Merck
• (4:03) When to expect data from its current clinical trials
• (5:10)  What's coming up for IMM 

 Note: This interview was filmed on 22 March 2022.